September 2013 Bayer Corporate Report Shows Apparent Progress In Settlement Negotiations, But A Number Of More Serious Cases Are Still Pending
According to Bayer corporate reports, the number of unsettled lawsuits involving YAZ / Yasmin / Ocella / Gianvi and blood clots, such as deep vein thrombosis (DVT) and/or pulmonary embolism (PE) cases, have remained well above 2000 cases during 2013, with there currently being about 2300 such claims.
From the Bayer Stockholders’ Newsletter, Financial Report as of September 30, 2013, Third quarter of 2013 (PDF document), at page 65:
As of October 18, 2013, the number of claimants in the pending lawsuits and claims in the United States totaled about 5,000 (excluding claims already settled). Claimants allege that they have suffered personal injuries, some of them fatal, from the use of Bayer’s drospirenone-containing oral contraceptive products such as Yasmin™ and/or YAZ™ or from the use of Ocella™ and/or Gianvi....
As of October 18, 2013, Bayer had reached agreements, without admission of liability, to settle the claims of approximately 7,660 claimants in the U.S. for a total amount of about US$1.575 billion. Bayer has only been settling claims in the U.S.for venous clot injuries (deep vein thrombosis or pulmonary embolism).... Such injuries are alleged by about 2,300 of the pending unsettled claimants. Bayer will continue to consider the option of settling such individual lawsuits in the U.S. on a case-by-case basis.
Free Case Evaluation
Strictly Confidential, No Obligation.
From our September 2013 update article, "YAZ / Yasmin / Ocella / Gianvi Blood Clot Lawsuits That Are Not Settled Yet: Number Increases, Indicating That These Legal Claims Continue To Be Filed In 2013", we get the earlier Bayer numbers of unsettled cases:
Previously, we reported that more than 2500 YAZ / Yasmin / Ocella / Gianvi lawsuits or legal claims involving blood clots, such as deep vein thrombosis (DVT) and/or pulmonary embolism (PE) cases, had not been settled as of April 15, 2013.
Now, from the Bayer Stockholders' Newsletter for Second quarter of 2013 we know that the number of unresolved pending DVT and PE blood clot-related lawsuits or claims subject to a so-called "tolling agreement" has increased by about 300....
A somewhat related item from this Bayer Stockholders’ Newsletter for the 3rd Quarter 2013; among "[t]he most important drug candidates in the approval process" as of October 17, 2013 is:
- YAZ™ Flex Plus U.S.A.; oral contraception with flexible dosage regimen
and folic acid supplementation
It remains to be seen whether there will be any court trials for YAZ, Yasmin, Ocella, Gianvi, Beyaz, and Safyral lawsuits involving arterial clots, which can cause strokes and other serious side effects. Reportedly, thus far the lawyers for Bayer have refused to negotiate these types of cases.